Research
Development of quinoline derivatives as dual EGFR/HDAC-2 inhibitors: design, synthesis, anticancer evaluation, and molecular dynamics simulations
Nature ·
The Brief
- A study reports the design and synthesis of quinoline derivatives as dual EGFR/HDAC-2 inhibitors.
- The work includes anticancer evaluation and molecular dynamics simulations.
- The source is a nature.com subject feed listing from 2026-11-09 with no summary provided.
Why it matters
It describes a candidate dual-target compound class for cancer research, which matters to medicinal chemists and cancer biologists, though the feed gives no detailed results.
Who’s affected
- medicinal chemists
- cancer researchers
- #quinoline
- #egfr
- #hdac-2
- #anticancer
- #molecular dynamics
- #drug design